TF Financial Corp (THRD)

Name: TF Financial Corp (THRD) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: TF Financial Corp (THRD)

Stock Card

$5.38

$0.00 (0.00%)

As on 13-Aug-2025 09:30EDT

Market cap

$243 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

0.9

Div. Yield

0 %

TF Financial Corp (THRD) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 5.38 High: 5.38

52 Week Range

Low: -- High: --

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.2 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-2.1
Debt to Equity

0
Book Value

$--
EPS

$-1.3
Face value

--
Shares outstanding

45,127,800

Years Aggregate

CFO

$--

EBITDA

$--

Net Profit

$--

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
TF Financial Corp (THRD)	-47.7	-1.3	4.5	-54.3	--	--	--
BSE Sensex^*	-8.8	0.6	1.8	-4.4	6.0	6.6	10.8
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 13-Aug-2025 | *As on 28-Aug-2026 | #As on 26-Oct-2023

Company	2024	2023
TF Financial Corp (THRD)	-6.1	155.1
S&P Small-Cap 600	7.0	13.9
BSE Sensex	8.1	18.7

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
TF Financial Corp (THRD)	5.4	242.8	0.1	-53.5	-138,120.8	-18.8	--	0.9
IGM Biosciences (IGMS)	1.3	76.6	145.1	-53.4	-26.7	-71.6	--	0.8

Shareholding Pattern

View Details

About TF Financial Corp (THRD)

Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell... surface receptor that serves as the master regulator of mast cell function and survival. It also develops THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated inflammatory diseases, respiratory, and gastrointestinal conditions. It has a license agreement with Novartis Pharma AG. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in San Francisco, California. Read more

CEO & Director

Ms. Natalie C. Holles
CEO & Director

Ms. Natalie C. Holles
Headquarters

San Francisco, CA
Website

https://www.thirdharmonicbio.com

FAQs for TF Financial Corp (THRD)

What is the current share price of TF Financial Corp (THRD) Today?

The share price of TF Financial Corp (THRD) is $5.38 (NASDAQ) as of 13-Aug-2025 09:30 EDT. TF Financial Corp (THRD) has given a return of -54.25% in the last 1 years.

What is the current PB & PE ratio of TF Financial Corp (THRD)?

Since, TTM earnings of TF Financial Corp (THRD) is negative, P/E ratio is not available.
The P/B ratio of TF Financial Corp (THRD) is 0.89 times as on 13-Aug-2025, a 83 discount to its peers’ median range of 5.35 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2024	9.35	1.49
2023	-14.21	1.63
2022	-4.49	0.59
2021	--	--
2020	--	--

What is the 52 Week High and Low of TF Financial Corp (THRD)?

The 52-week high and low of TF Financial Corp (THRD) are Rs -- and Rs -- as of 30-Aug-2026.

What is the market cap of TF Financial Corp (THRD)?

TF Financial Corp (THRD) has a market capitalisation of $ 243 Mln as on 13-Aug-2025. As per SEBI classification, it is a Small Cap company.

Should I invest in TF Financial Corp (THRD)?

Before investing in TF Financial Corp (THRD), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.